Onxeo: Introducing Platon; Asidna Approaches Phase I
Edison | Nov 30, 2017 12:10AM ET
Onxeo (PA:C4X)has experienced a volatile 2017 mainly due to Livatag’s Phase III ReLive not meeting its primary endpoint. The out-licensing of Validive, fresh data from several preclinical studies with core assets – AsiDNA and belinostat combinations – were more positive recent developments. Although the share price halved after the disappointing ReLive data, the asset portfolio has been radically reshaped to focus on DNA break repair inhibition and epigenetics and Onxeo has cash reach until 2020. Our updated valuation is €218m (vs €350m) or €4.3/share.
ReLive did not meet primary endpoint
As announced in September 2017, the Phase III ReLive trial with Livatag (proprietary doxorubicin-loaded nanoparticles) in advanced hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving survival as a second line therapy in HCC patients over the comparison standard of care arm. Unexpected high survival in the comparison arm was the main reason given by the company. Onxeo noted that Livatag tended to show a similar efficacy as recently approved regorafenib in a subpopulation of HCC patients with well-preserved liver function (inter-trial comparison). The unmet need is significant in HCC; therefore, while Onxeo has discontinued internal development for Livatag, it plans to explore all options for licensing. However, we do not expect rapid progress in this area.
To read the entire report Please click on the pdf File Below:
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.